{"id":"fasedienol-nasal-spray","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fasedienol acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, a glutamate receptor subtype implicated in depression pathophysiology. By blocking NMDA receptor signaling, it is hypothesized to rapidly restore synaptic plasticity and produce fast-acting antidepressant effects. The nasal spray formulation enables direct brain delivery and rapid systemic absorption, potentially providing faster symptom relief compared to oral antidepressants.","oneSentence":"Fasedienol is a NMDA receptor antagonist administered as a nasal spray for rapid-onset treatment of depression.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:17.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder (Phase 3)"},{"name":"Treatment-resistant depression (exploratory)"}]},"trialDetails":[{"nctId":"NCT06809179","phase":"PHASE2","title":"A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder","status":"RECRUITING","sponsor":"VistaGen Therapeutics, Inc.","startDate":"2025-01-09","conditions":"Social Anxiety Disorder","enrollment":60},{"nctId":"NCT06615557","phase":"PHASE3","title":"Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)","status":"RECRUITING","sponsor":"VistaGen Therapeutics, Inc.","startDate":"2024-09-16","conditions":"Social Anxiety Disorder (SAD)","enrollment":236},{"nctId":"NCT06358651","phase":"PHASE3","title":"Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"VistaGen Therapeutics, Inc.","startDate":"2024-03-28","conditions":"Social Anxiety Disorder","enrollment":238}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fasedienol Nasal Spray","genericName":"Fasedienol Nasal Spray","companyName":"VistaGen Therapeutics, Inc.","companyId":"vistagen-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fasedienol is a NMDA receptor antagonist administered as a nasal spray for rapid-onset treatment of depression. Used for Major depressive disorder (Phase 3), Treatment-resistant depression (exploratory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}